Grant Award
The award payment offers each institution $120,000 over a 2-year period. The goal of this grant is to support the institution in developing the new program, as well as provide salary assistance for two consecutive residency years.
TRAIN Pharmacy Grant
Grant Funding for PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management
This recently established 1-year residency, authorized by ASHP, will increase the number of expert clinicians equipped to effectively manage patients at risk for thrombosis and bleeding, and support the creation of anticoagulation stewardship programs nationwide.
This recently established 1-year residency, authorized by ASHP, will increase the number of expert clinicians equipped to effectively manage patients at risk for thrombosis and bleeding, and support the creation of anticoagulation stewardship programs nationwide.
TRAIN Spring 2025 Application Cycle
The TRAIN 2025 funding cycle is now open!
AC Forum will award one 2-year grant in the Spring 2025 application cycle. The funding will begin for residents starting in July 2026.
Please visit the application site and submit an application here.
View PDF of application.
**Note about application site: The site will not allow candidates to go back into the system to correct applications. Please draft your application using the WORD DOC version in advance of submitting.
The deadline for applications is by or before Friday, February 14.
Eligibility for AC Forum TRAIN Pharmacy Grant
Applicants must be US-based organizations with existing ASHP-accredited pharmacy residency programs and advanced pharmacy practices in the prevention and treatment of thrombosis and bleeding.
The Residency Program Director (RPD) must have either 1) completed a PGY2 residency in a related specialty area and have 3+ years of practice experience OR 2) have 5 years of practice experience in a relevant specialty area. The RPD should also be board certified in either Pharmacotherapy, Ambulatory Care, or Cardiology or have obtained recognition as a Certified Anticoagulation Care Provider from the National Certification Board for Anticoagulation Providers. The Director must also actively practice in a clinical area involving anticoagulation management.
Each awarded residency program will select the PGY2 resident via their own selection process, using their own criteria such as clinical excellence, academic potential, leadership ability, teaching skills, and demonstrated interest in thrombosis and hemostasis-related care. The AC Forum recommends that diversity, equity, and inclusion be prioritized as part of the selection process at each institution.
Grant Application Process
Sites will be asked to provide the following in the application:
- Program contact information
- List of current PGY2 pharmacy residencies
- Candidate recruitment plan
- Budget breakdown
- Program description that includes:
- Brief curriculum outline and learning experiences you intend to offer. Distinguish between required and elective experiences and indicate whether each is a formal block or longitudinal.
- The institution’s current service(s) in thrombosis and hemostasis management
- The pharmacy department’s involvement in managing thrombosis and hemostasis
- Potential preceptors to be involved in residency training (include a short bio of each faculty member). Please also identify a proposed residency program director.
- Research opportunities for the resident
- Letter of support from the Director of Pharmacy
- Letter of support from a physician champion with a practice focus in thrombosis and hemostasis
Review Process and Notification
Institutions will be selected by an Anticoagulation Forum Review Committee based on their ability to train well-rounded residents, clinical and research expertise in relevant areas, and the program’s focus on thrombosis and hemostasis management. Reviewers with a conflict of interest will be recused from reviewing the specific application. Selected institutions will be notified of grant awards and will be required to sign a Grant Agreement with the Anticoagulation Forum.
Questions the Review Committee will consider include:
- Does the program have faculty that can provide robust training?
- What is the likelihood strong residents will apply/accept the program?
- What types of research opportunities exist for/within the program?
- How does the pharmacy department drive thrombosis and hemostasis clinical initiatives?
- What is the likelihood the resident will have an impact in the field?
- What is the likelihood of job placement after residency?
Process and Timeline
Awarded sites will be required to pursue accreditation through ASHP. The residency accreditation process is independent from the TRAIN grant program. Click “Learn More” for official resources for ASHP accreditation.
PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management Learning Objectives
The PGY2 residency follows program competencies defined by ASHP.
TRAIN Pharmacy Seminar Series
Residents, along with their RPDs, will be expected to participate in a virtual seminar series moderated by faculty from each of the AC Forum PGY2 Residency sites. Seminars will focus on key subject matter topics within the thrombosis and hemostasis curriculum, as well as those related to career development. Residents will also have the opportunity to present complex cases to senior panelists.
RPDs and their faculty will work collaboratively to develop the content and syllabus for the seminar series, with support from the Anticoagulation Forum.
Financial Disclosure and Compliance
Institutions must be able to accept grant funding that may be subject to Sunshine Act reporting. The Anticoagulation Forum may be required to report information on the Residency award institution, Residency Program Director, resident, or other details of the program to AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc. to comply with the Sunshine Act.
Funding for the TRAIN Pharmacy Grant is provided by AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc.
v>
Institutions must be able to accept grant funding that may be subject to Sunshine Act reporting. The Anticoagulation Forum may be required to report information on the Residency award institution, Residency Program Director, resident, or other details of the program to AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc. to comply with the Sunshine Act. Funding for the TRAIN Pharmacy Grant is provided by AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc.
v> Resources
The following ACF resources may be of value to organizations seeking to establish residency programs and expand Anticoagulation Stewardship initiatives.